116 related articles for article (PubMed ID: 38225776)
1. Evaluation of Interleukin-17 A Levels in Patients with Breast Carcinoma.
El-Batal HM; Kamel MM; Moaz I; Gohar NM
Egypt J Immunol; 2024 Jan; 31(1):174-183. PubMed ID: 38225776
[TBL] [Abstract][Full Text] [Related]
2. IL-6, IL-8 and TNF-α levels correlate with disease stage in breast cancer patients.
Ma Y; Ren Y; Dai ZJ; Wu CJ; Ji YH; Xu J
Adv Clin Exp Med; 2017; 26(3):421-426. PubMed ID: 28791816
[TBL] [Abstract][Full Text] [Related]
3. Targeting of interleukin (IL)-17A inhibits PDL1 expression in tumor cells and induces anticancer immunity in an estrogen receptor-negative murine model of breast cancer.
Ma YF; Chen C; Li D; Liu M; Lv ZW; Ji Y; Xu J
Oncotarget; 2017 Jan; 8(5):7614-7624. PubMed ID: 27935862
[TBL] [Abstract][Full Text] [Related]
4. Association of serum interleukin-10, interleukin-17A and transforming growth factor-α levels with human benign and malignant breast diseases.
Lv Z; Liu M; Shen J; Xiang D; Ma Y; Ji Y
Exp Ther Med; 2018 Jun; 15(6):5475-5480. PubMed ID: 29904427
[TBL] [Abstract][Full Text] [Related]
5. Circulating levels of interleukin-17A, tumor necrosis factor-alpha, interleukin-18, interleukin-10, and cognitive performance of patients with relapsing-remitting multiple sclerosis.
Trenova AG; Slavov GS; Draganova-Filipova MN; Mateva NG; Manova MG; Miteva LD; Stanilova SA
Neurol Res; 2018 Mar; 40(3):153-159. PubMed ID: 29297273
[TBL] [Abstract][Full Text] [Related]
6. Serum profiles of pro-inflammatory and anti-inflammatory cytokines in non-hospitalized patients with mild/moderate COVID-19 infection.
Majeed AY; Zulkafli NES; Ad'hiah AH
Immunol Lett; 2023 Aug; 260():24-34. PubMed ID: 37339685
[TBL] [Abstract][Full Text] [Related]
7. Oral squamous cell carcinoma-derived EVs promote tumor progression by regulating inflammatory cytokines and the IL-17A-induced signaling pathway.
Li R; Zhou Y; Zhang M; Xie R; Duan N; Liu H; Qin Y; Ma J; Li Z; Ye P; Wang W; Wang X
Int Immunopharmacol; 2023 May; 118():110094. PubMed ID: 37030119
[TBL] [Abstract][Full Text] [Related]
8. Interleukin (IL)-17A in triple-negative breast cancer: a potent prognostic factor associated with intratumoral neutrophil infiltration.
Khalid F; Takagi K; Sato A; Yamaguchi M; Guestini F; Miki Y; Miyashita M; Hirakawa H; Ohi Y; Rai Y; Sagara Y; Sasano H; Suzuki T
Breast Cancer; 2023 Sep; 30(5):748-757. PubMed ID: 37178415
[TBL] [Abstract][Full Text] [Related]
9. Interleukin 17 in early invasive breast cancer.
Popović M; Dedić Plavetić N; Vrbanec D; Marušić Z; Mijatović D; Kulić A
Front Oncol; 2023; 13():1171254. PubMed ID: 37427128
[TBL] [Abstract][Full Text] [Related]
10. Interleukin-17A promotes tongue squamous cell carcinoma metastasis through activating miR-23b/versican pathway.
Wei T; Cong X; Wang XT; Xu XJ; Min SN; Ye P; Peng X; Wu LL; Yu GY
Oncotarget; 2017 Jan; 8(4):6663-6680. PubMed ID: 28035060
[TBL] [Abstract][Full Text] [Related]
11. Correlation between IL-17A expression in nasopharyngeal carcinoma tissues and cells and pathogenesis of NPC in endemic areas.
Wang LX; Ma RX; Di LL; Peng XB; Kang ZP; Zhong S
Eur Arch Otorhinolaryngol; 2019 Nov; 276(11):3131-3138. PubMed ID: 31456038
[TBL] [Abstract][Full Text] [Related]
12. Serum CCL20 combined with IL-17A as early diagnostic and prognostic biomarkers for human colorectal cancer.
Wang D; Yuan W; Wang Y; Wu Q; Yang L; Li F; Chen X; Zhang Z; Yu W; Maimela NR; Cao L; Wang D; Wang J; Sun Z; Liu J; Zhang Y
J Transl Med; 2019 Aug; 17(1):253. PubMed ID: 31387598
[TBL] [Abstract][Full Text] [Related]
13. IL-17A is produced by breast cancer TILs and promotes chemoresistance and proliferation through ERK1/2.
Cochaud S; Giustiniani J; Thomas C; Laprevotte E; Garbar C; Savoye AM; Curé H; Mascaux C; Alberici G; Bonnefoy N; Eliaou JF; Bensussan A; Bastid J
Sci Rep; 2013 Dec; 3():3456. PubMed ID: 24316750
[TBL] [Abstract][Full Text] [Related]
14. The role of Interleukin-17A and Interleukin-17E in multiple myeloma patients.
Lemancewicz D; Bolkun L; Jablonska E; Czeczuga-Semeniuk E; Kostur A; Kloczko J; Dzieciol J
Med Sci Monit; 2012 Jan; 18(1):BR54-59. PubMed ID: 22207110
[TBL] [Abstract][Full Text] [Related]
15. Analysis of pro- and anti-inflammatory cytokine gene variants and serum cytokine levels as prognostic markers in breast cancer.
Kaur RP; Vasudeva K; Singla H; Benipal RPS; Khetarpal P; Munshi A
J Cell Physiol; 2018 Dec; 233(12):9716-9723. PubMed ID: 30078181
[TBL] [Abstract][Full Text] [Related]
16. Serum soluble ST2 is associated with ER-positive breast cancer.
Lu DP; Zhou XY; Yao LT; Liu CG; Ma W; Jin F; Wu YF
BMC Cancer; 2014 Mar; 14():198. PubMed ID: 24636276
[TBL] [Abstract][Full Text] [Related]
17. Analytical Computation of Interleukin17A Activity in Breast Cancer Patients Using Bioinformatics Methods.
Mohammed AS; Al-Janabi AA
Arch Razi Inst; 2021 Oct; 76(4):895-901. PubMed ID: 35096325
[TBL] [Abstract][Full Text] [Related]
18. Cytokine profiles in patients with newly diagnosed multiple myeloma: Survival is associated with IL-6 and IL-17A levels.
Gu J; Huang X; Zhang Y; Bao C; Zhou Z; Jin J
Cytokine; 2021 Feb; 138():155358. PubMed ID: 33183958
[TBL] [Abstract][Full Text] [Related]
19. Association analysis of IL-17A and IL-17F polymorphisms in Chinese Han women with breast cancer.
Wang L; Jiang Y; Zhang Y; Wang Y; Huang S; Wang Z; Tian B; Yang Y; Jiang W; Pang D
PLoS One; 2012; 7(3):e34400. PubMed ID: 22461912
[TBL] [Abstract][Full Text] [Related]
20. The prognostic role of interleukin-8 (IL-8) and matrix metalloproteinases -2 and -9 in lymph node-negative untreated breast cancer patients.
Milovanovic J; Todorovic-Rakovic N; Abu Rabi Z
J BUON; 2013; 18(4):866-73. PubMed ID: 24344010
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
